The March 2019 quarter revenue stood at Rs. 7173.00 millions, up 16.12% as compared to Rs. 6177.00 millions during the corresponding quarter last year.Net profit stood at Rs. 929.00  millions  compared to Rs. 825.00 millions in the corresponding previous quarter,high by 12.61%.The company reported a good operating profit of 1768.00 millions compared to 1570.00 millions of corresponding previous quarter. (Rs. in Million) Quarter ended Year to Date Year ended 201903 201803 % Var 201903 201803 % Var 201812 201712 % Var Sales 7173.00 6177.00 16.12 7173.00 6177.00 16.12 27708.00 24914.00 11.21 Other Income 230.00 226.00 1.77 230.00 226.00 1.77 897.00 807.00 11.15 PBIDT 1768.00 1570.00 12.61 1768.00 1570.00 12.61 7132.00 6179.00 15.42 Interest 0.00 0.00 0.00 0.00 0.00 0.00 7.00 11.00 -36.36 PBDT 1768.00 1570.00 12.61 1768.00 1570.00 12.61 7125.00 6168.00 15.52 Depreciation 261.00 254.00 2.76 261.00 254.00 2.76 1027.00 1022.00 0.49 PBT 1507.00 1316.00 14.51 1507.00 1316.00 14.51 6098.00 5146.00 18.50 TAX 578.00 491.00 17.72 578.00 491.00 17.72 2292.00 1886.00 21.53 Deferred Tax -12.00 -12.00 0.00 -12.00 -12.00 0.00 -117.00 25.00 -568.00 PAT 929.00 825.00 12.61 929.00 825.00 12.61 3806.00 3260.00 16.75 Equity 230.00 230.00 0.00 230.00 230.00 0.00 230.00 230.00 0.00 PBIDTM(%) 24.65 25.42 -3.03 24.65 25.42 -3.03 25.74 24.80 3.78

Sanofi India is currently trading at Rs. 6413.30, up by 43.50 points or 0.68% from its previous closing of Rs. 6369.80 on the BSE.The scrip opened at Rs. 6350.00 and has touched a high and low of Rs. 6445.00 and Rs. 6350.00 respectively. So far 92 shares were traded on the counter.The BSE group `A` stock of face value Rs. 10 has touched a 52 week high of Rs. 6840.05 on 10-Sep-2018 and a 52 week low of Rs. 4675.00 on 22-Jan-2018.Last one week high and low of the scrip stood at Rs. 6445.00 and Rs. 6155.00 respectively. The current market cap of the company is Rs. 14770.23 crore.The promoters holding in the company stood at 60.40%, while Institutions and Non-Institutions held 29.07% and 10.54% respectively.Sanofi India has launched the new advertisement campaign for their topical analgesic - Combiflam ICYHOT to provide effective relief to people suffering from strong pains.The film conceptualized by Ogilvy, is a clutter breaking advertisement with humorous undertones that is bringing smiles on the face of viewers. The advertisement campaign was developed on the insight that pain can weigh one down and can derail one’s day to day life. Effective respite from pain can help people get back on track and move forward.Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets and animal health.

Sanofi India is currently trading at Rs. 6168.00, up by 56.25 points or 0.92% from its previous closing of Rs. 6111.75 on the BSE.The scrip opened at Rs. 6129.95 and has touched a high and low of Rs. 6243.45 and Rs. 6129.95 respectively. So far 657 shares were traded on the counter.The BSE group `A` stock of face value Rs. 10 has touched a 52 week high of Rs. 6,243.45 on 07-Aug-2018 and a 52 week low of Rs. 3901.00 on 06-Sep-2017.Last one week high and low of the scrip stood at Rs. 6,243.45 and Rs. 5,950.00 respectively. The current market cap of the company is Rs. 14197.23 crore.The promoters holding in the company stood at 60.40%, while Institutions and Non-Institutions held 28.22% and 11.38% respectively.Sanofi’s specialty care global business unit -- Sanofi Genzyme has launched its multiple sclerosis treatment drug ‘Aubagio’ in India. The drug offers patients diagnosed with multiple sclerosis the efficacy and convenience of once-a-day oral treatment.Aubagio is a differentiated disease modifying therapy that blocks the enzyme involved in multiplication of overactive immune cells.Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets and animal health.

Sanofi is currently trading at Rs. 5250.00, up by 50.00 points or 0.96% from its previous closing of Rs. 5200.00 on the BSE.The scrip opened at Rs. 5230.00 and has touched a high and low of Rs. 5266.00 and Rs. 5230.00 respectively. So far 15260 shares were traded on the counter.The BSE group `A` stock of face value Rs. 10 has touched a 52 week high of Rs. 5995.00 on 28-Mar-2018 and a 52 week low of Rs. 3901.00 on 06-Sep-2017.Last one week high and low of the scrip stood at Rs. 5295.00 and Rs. 4865.00 respectively. The current market cap of the company is Rs. 12091.08 crore.The promoters holding in the company stood at 60.40%, while Institutions and Non-Institutions held 28.29% and 11.32% respectively.Sanofi has launched the first initiative under its pain education campaign - `Pain Clinics`. This phase comprises a series of doctor and pain expert videos on a dedicated YouTube channel to generate awareness and educate people, so that they can understand and treat pain in an informed and responsible manner.Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets and animal health.

The Revenue for the quarter ended  March 2018 of Rs. 6177.00 millions grew by 11.72 % from Rs. 5529.00 millions.The company has announced a 37.50% increase in its profits to Rs . 825.00  millions for the  quarter ended March 2018 compared to Rs. 600.00 millions in the corresponding quarter in the previous year.The company reported a good operating profit of 1570.00 millions compared to 1174.00 millions of corresponding previous quarter. (Rs. in Million) Quarter ended Year to Date Year ended 201803 201703 % Var 201803 201703 % Var 201712 201612 % Var Sales 6177.00 5529.00 11.72 6177.00 5529.00 11.72 24914.00 24197.00 2.96 Other Income 226.00 159.00 42.14 226.00 159.00 42.14 807.00 664.00 21.54 PBIDT 1570.00 1174.00 33.73 1570.00 1174.00 33.73 6179.00 6015.00 2.73 Interest 0.00 4.00 0.00 0.00 4.00 0.00 11.00 23.00 -52.17 PBDT 1570.00 1170.00 34.19 1570.00 1170.00 34.19 6168.00 5992.00 2.94 Depreciation 254.00 253.00 0.40 254.00 253.00 0.40 1022.00 1188.00 -13.97 PBT 1316.00 917.00 43.51 1316.00 917.00 43.51 5146.00 4804.00 7.12 TAX 491.00 317.00 54.89 491.00 317.00 54.89 1886.00 1762.00 7.04 Deferred Tax -12.00 -61.00 -80.33 -12.00 -61.00 -80.33 25.00 -166.00 -115.06 PAT 825.00 600.00 37.50 825.00 600.00 37.50 3260.00 3042.00 7.17 Equity 230.00 230.00 0.00 230.00 230.00 0.00 230.00 230.00 0.00 PBIDTM(%) 25.42 21.23 19.70 25.42 21.23 19.70 24.80 24.86 -0.23

A fair growth of 10.83% in the revenue at Rs. 6704.00 millions was reported in the December 2017 quarter as compared to Rs. 6049.00 millions during year-ago period.The company has announced a 44.49% increase in its profits to Rs . 760.00  millions for the  quarter ended December 2017 compared to Rs. 526.00 millions in the corresponding quarter in the previous year.Operating profit surged to 1526.00 millions from the corresponding previous quarter of 1241.00 millions. (Rs. in Million) Quarter ended Year to Date Year ended 201712 201612 % Var 201712 201612 % Var 201712 201612 % Var Sales 6704.00 6049.00 10.83 24914.00 24197.00 2.96 24914.00 24197.00 2.96 Other Income 182.00 152.00 19.74 807.00 664.00 21.54 807.00 664.00 21.54 PBIDT 1526.00 1241.00 22.97 6179.00 6015.00 2.73 6179.00 6015.00 2.73 Interest 11.00 12.00 -8.33 11.00 23.00 -52.17 11.00 23.00 -52.17 PBDT 1515.00 1229.00 23.27 6168.00 5992.00 2.94 6168.00 5992.00 2.94 Depreciation 257.00 381.00 -32.55 1022.00 1188.00 -13.97 1022.00 1188.00 -13.97 PBT 1258.00 848.00 48.35 5146.00 4804.00 7.12 5146.00 4804.00 7.12 TAX 498.00 322.00 54.66 1886.00 1762.00 7.04 1886.00 1762.00 7.04 Deferred Tax 77.00 -71.00 -208.45 25.00 -166.00 -115.06 25.00 -166.00 -115.06 PAT 760.00 526.00 44.49 3260.00 3042.00 7.17 3260.00 3042.00 7.17 Equity 230.00 230.00 0.00 230.00 230.00 0.00 230.00 230.00 0.00 PBIDTM(%) 22.76 20.52 10.95 24.80 24.86 -0.23 24.80 24.86 -0.23

Sanofi India is currently trading at Rs. 4160.00, up by 102.95 points or 2.54% from its previous closing of Rs. 4057.05 on the BSE.The scrip opened at Rs. 4074.65 and has touched a high and low of Rs. 4160.00 and Rs. 4074.65 respectively. So far 509 shares were traded on the counter.The BSE group `A` stock of face value Rs. 10 has touched a 52 week high of Rs. 4930.00 on 29-Mar-2017 and a 52 week low of Rs. 3901.00 on 06-Sep-2017.Last one week high and low of the scrip stood at Rs. 4160.00 and Rs. 4022.00 respectively. The current market cap of the company is Rs. 9534.68 crore.The promoters holding in the company stood at 60.40%, while Institutions and Non-Institutions held 27.95% and 11.66% respectively.Sanofi India has expanded its consumer healthcare portfolio with a new addition in the pain-care segment – Combiflam ICYHOT, a topical analgesic. This over-the-counter (OTC) product is available in two formats — gel and spray, for instant and long-lasting relief to people suffering from muscle pains and sprains. On application of Combiflam ICYHOT, it produces an icy and a hot sensation. The icy action reduces the pain, while the hot action relaxes stiff muscles to give effective pain relief. Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets and animal health.

Sanofi India is currently trading at Rs. 3989.00, up by 35.70 points or 0.90% from its previous closing of Rs. 3953.30 on the BSE.The scrip opened at Rs. 4009.30 and has touched a high and low of Rs. 4009.30 and Rs. 3955.00 respectively. So far 32 shares were traded on the counter.The BSE group `A` stock of face value Rs. 10 has touched a 52 week high of Rs. 4930.00 on 29-Mar-2017 and a 52 week low of Rs. 3901.00 on 06-Sep-2017.Last one week high and low of the scrip stood at Rs. 4080.45 and Rs. 3901.00 respectively. The current market cap of the company is Rs. 9186.92 crore.The promoters holding in the company stood at 60.40%, while institutions and non-institutions held 27.95% and 11.66% respectively.Sanofi India has expanded its consumer healthcare portfolio with a new addition in the pain-care segment - Combiflam ICYHOT, a topical analgesic. This over-the-counter (OTC) product is available in two formats - gel and spray, for instant and long-lasting relief to people suffering from muscle pains and sprains. On application of Combiflam ICYHOT, it produces an icy and a hot sensation. The icy action reduces the pain, while the hot action relaxes stiff muscles to give effective pain relief.Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets and animal health.

Sanofi India is currently trading at Rs. 4680.95, up by 68.95 points or 1.50% from its previous closing of Rs. 4612.00 on the BSE.The scrip opened at Rs. 4650.00 and has touched a high and low of Rs. 4680.95 and Rs. 4570.00 respectively. The BSE group `A` stock of face value Rs. 10 has touched a 52 week high of Rs. 4930.00 on 29-Mar-2017 and a 52 week low of Rs. 4005.00 on 28-Feb-2017.Last one week high and low of the scrip stood at Rs. 4680.95 and Rs. 4525.10 respectively. The current market cap of the company is Rs. 10651.66 crore.The promoters holding in the company stood at 60.40%, while Institutions and Non-Institutions held 28.95% and 10.65% respectively.Sanofi India is expecting a muted growth in the domestic market in 2017 and therefore the company will be focusing to drive the volume growth as well as exports. The focus will be to increase the domestic volume growth on one side and drive exports on the other, as the latter looks more promising.Moreover, to shore up exports, the company is in the process of unveiling a strategic project to boost its competitiveness and productivity through operational improvement as part of a specially designed programme named ‘Fit for Future’ at both its manufacturing sites.Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets and animal health.

The Exchange had sought clarification from Sanofi India with respect to news appearing in The Hindu on March 2, 2017 titled ‘Sanofi, Boehringer close business swap.’The above information is a part of company’s filings submitted to BSE.

The Exchange has sought clarification from Sanofi India with respect to news article appearing on The Hindu on March 2, 2017 titled ‘Sanofi, Boehringer close business swap.’The above information is a part of company’s filings submitted to BSE.

Sanofi India is currently trading at Rs. 4620.50, up by 120.85 points or 2.69% from its previous closing of Rs. 4499.65 on the BSE.The scrip opened at Rs. 4646.45 and has touched a high and low of Rs. 4650.00 and Rs. 4600.00 respectively. So far 516 shares were traded on the counter.The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 4770.00 on 04-Jul-2016 and a 52 week low of Rs. 3676.00 on 24-Jul-2015.Last one week high and low of the scrip stood at Rs. 4701.00 and Rs. 4450.00 respectively. The current market cap of the company is Rs. 10681.14 crore.The promoters holding in the company stood at 60.40%, while Institutions and Non-Institutions held 29.40% and 10.20% respectively.Sanofi India has registered a surge of 32.87% in its net profit at Rs 85.30 crore for the second quarter ended June 30, 2016 as compared to Rs 64.20 crore for the same quarter in the previous year. Total income of the company increased by 11.58% at Rs 624.40 crore for the quarter ended June 30, 2016 as compared Rs 559.60 crore for the corresponding quarter previous year.Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets and animal health.